Taken together our findings demonstrated that CYLD was a DDP sensitizer which may be as a new biomarker for ovarian cancer DDP resistance, the HER3 inhibitor and ABCB1 inhibitor combination greatly increased cisplatin treatment effect, and made DDP resistant OC cells to become sensitive cells (Fig. 9D). Here, CYLD is linked to ovarian cancer.